Overview


According to FutureWise analysis, the market for Altapharma is expected to grow with a CAGR of 8.8% over the forecast period 2023-2031, and reach a market value of US$ 346.33 Billion by 2031.

Altapharma is a brand name associated with various products, primarily in the healthcare and wellness sectors. It is not specific to one company or manufacturer but a label that several companies use to market their products. Altapharma products are commonly found in pharmacies and supermarkets in certain regions.

Altapharma products typically include various health and wellness items, such as dietary supplements, vitamins, minerals, herbal remedies, over-the-counter medications, personal care products, and sometimes even non-medical items like wellness accessories or health-related literature. Since Altapharma is not tied to a single manufacturer, the specific products and their formulations may vary depending on the company using the brand. Different manufacturers may have varying quality standards and sources for their ingredients, so consumers need to read labels and consult healthcare professionals when necessary. Altapharma products are often marketed to promote health, wellness, and self-care. They are designed to support general health, provide essential nutrients, or address specific health concerns.  Altapharma products were primarily available in certain regions, particularly in Germany, where they are commonly found in the drugstore chain Rossmann. Availability may vary by country and region.

FutureWise Market Research has published a report that provides an insightful analysis of Altapharma Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Altapharma Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer
  • Roche
  • Johnson & Johnson
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Sanofi
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Teva Pharmaceutical
  • Bayer
  • Novo Nordisk
  • Allergan
  • Gilead Sciences
  • Boehringer Ingelheim
  • Takeda Pharmaceutical
  • Biogen

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Altapharma Market:

  • In 2022, the U.S. FDA approved AstraZeneca for its drug Farxiga, which is intended to treat chronic kidney disease in patients, whether they have diabetes or not.
  • In 2021, Pfizer launched Cibinqo, an antibody therapy developed explicitly for treating moderate-to-severe atopic dermatitis in adult patients.

The surge in health and wellness consciousness among consumers, coupled with a heightened emphasis on self-care and preventive healthcare, drives the demand for Altapharma products. Altapharma products often offer competitive prices compared to branded counterparts, attracting cost-conscious consumers and driving the market. Partnerships with drugstore chains and supermarkets like Rossmann provide accessibility and exposure for Altapharma products. Altapharma provides extensive offerings, encompassing vitamins, supplements, personal care items, and over-the-counter medications. This diverse product range effectively serves various consumers with diverse health requirements. Adhering to quality and regulatory requirements is essential for maintaining consumer trust and compliance with industry standards and thus drives the market.

However, there are significant restraints for this market. Altapharma faces competition from well-known, established brands in the healthcare and wellness industry. Building brand recognition and consumer loyalty can be challenging for private-label products like Altapharma compared to longstanding, recognized brands. Some consumers may associate private label products with lower quality than well-known brands, impacting purchasing decisions. Adherence to strict regulatory standards is crucial, and any lapses in quality or safety can significantly affect the brand's reputation and hence constraints the market growth.

By Product

  • Vitamins and Minerals
  • Dietary Supplements
  • Herbal and Natural Products
  • Sports Nutrition
  • Baby and Child Nutrition
  • Beauty and Skincare Supplements
  • Specialty Health Products

By Target Demographics

  • Adults
  • Children
  • Seniors
  • Athletes and Fitness Enthusiasts
  • Pregnant and Nursing Women
  • Individuals with Specific Health Conditions

By Distribution Channels

  • Retail Pharmacies
  • Supermarkets and Hypermarkets
  • Online Retailers and E-commerce
  • Health and Wellness Stores
  • Specialty Nutrition Stores

By Health Benefits

  • Immune Support
  • Bone and Joint Health
  • Heart Health
  • Digestive Health
  • Cognitive Health
  • Energy and Vitality
  • Skin and Hair Health

By Packaging Types

  • Bottles and Jars
  • Blister Packs
  • Sachets and Stick Packs
  • Liquid Formulations
  • Softgels and Capsules

By Certification and Claims

  • Organic and Natural
  • Non-GMO
  • Gluten-Free
  • Vegan or Vegetarian
  • Scientifically Backed Formulations

By Price Range

  • Affordable Mass-Market Products
  • Premium and Specialty Products

By Consumer Preferences

  • Traditional Supplements
  • Trendy and Innovative Formulations
  • Local and Sustainable Sourcing

By Marketing Focus

  • Health and Wellness Promotion
  • Fitness and Sports Performance
  • Beauty and Anti-Aging Benefits
  • Specialized Nutritional Needs

By Packaging Sizes

  • Single-Dose Packets
  • Small, Medium, and Large Bottles
  • Bulk Packs

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the increased adoption of advanced therapeutics and the presence of significant market players in the region. Conversely, the European region is poised for substantial expansion in the forecast period due to the surge in the prevalence of chronic diseases and favorable government initiatives in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Altapharma Market By Product, By Target Demographics, By Distribution Channels, By Health Benefits, By Packaging Types, By Certification and Claims, By Price Range, By Consumer Preferences, By Marketing Focus, By Packaging Sizes, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Altapharma Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Altapharma Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Altapharma Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Altapharma Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Vitamins and Minerals
        2. Dietary Supplements
        3. Herbal and Natural Products
        4. Sports Nutrition
        5. Baby and Child Nutrition
        6. Beauty and Skincare Supplements
        7. Specialty Health Products

  • 8.  Altapharma Market, By Target Demographics Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Adults
        2. Children
        3. Seniors
        4. Athletes and Fitness Enthusiasts
        5. Pregnant and Nursing Women
        6. Individuals with Specific Health Conditions

  • 9.  Altapharma Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Retail Pharmacies
        2. Supermarkets and Hypermarkets
        3. Online Retailers and E-commerce
        4. Health and Wellness Stores
        5. Specialty Nutrition Stores

  • 10.  Altapharma Market, By Health Benefits Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Immune Support
        2. Bone and Joint Health
        3. Heart Health
        4. Digestive Health
        5. Cognitive Health
        6. Energy and Vitality
        7. Skin and Hair Health

  • 11.  Altapharma Market, By Packaging Types Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Bottles and Jars
        2. Blister Packs
        3. Sachets and Stick Packs
        4. Liquid Formulations
        5. Softgels and Capsules

  • 12.  Altapharma Market, By Certification and Claims Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Organic and Natural
        2. Non-GMO
        3. Gluten-Free
        4. Vegan or Vegetarian
        5. Scientifically Backed Formulations

  • 13.  Altapharma Market, By Price Range Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Affordable Mass-Market Products
        2. Premium and Specialty Products

  • 14.  Altapharma Market, By Consumer Preferences Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Traditional Supplements
        2. Trendy and Innovative Formulations
        3. Local and Sustainable Sourcing

  • 15.  Altapharma Market, By Marketing Focus Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Health and Wellness Promotion
        2. Fitness and Sports Performance
        3. Beauty and Anti-Aging Benefits
        4. Specialized Nutritional Needs

  • 16.  Altapharma Market, By Packaging Sizes Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Single-Dose Packets
        2. Small, Medium, and Large Bottles
        3. Bulk Packs

  • 17.  North America Altapharma Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 18.  Latin America Altapharma Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 19.  Europe Altapharma Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 20.  Asia Pacific Altapharma Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 21.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 22.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 23.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Roche
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Johnson & Johnson
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Novartis
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Merck & Co
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. GlaxoSmithKline
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Sanofi
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. AbbVie
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Amgen
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. AstraZeneca
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Bristol-Myers Squibb
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Eli Lilly
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Teva Pharmaceutical
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Bayer
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Novo Nordisk
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. Allergan
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. Gilead Sciences
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview
        18. Boehringer Ingelheim
           18.1. Company Overview
           18.2. Product Portfolio
           18.3. SWOT Analysis
           18.4. Financial Overview
           18.5. Strategic Overview
        19. Takeda Pharmaceutical
           19.1. Company Overview
           19.2. Product Portfolio
           19.3. SWOT Analysis
           19.4. Financial Overview
           19.5. Strategic Overview
        20. Biogen
           20.1. Company Overview
           20.2. Product Portfolio
           20.3. SWOT Analysis
           20.4. Financial Overview
           20.5. Strategic Overview

  • 24.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 25.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients